Jun Li1, Elizabeth Humes2, Jennifer S Lee2, Keri N Althoff2, Jonathan A Colasanti3, Ronald J Bosch4, Michael Horberg5, Peter F Rebeiro6, Michael J Silverberg7, Ank E Nijhawan8, Angela Parcesepe9, John Gill10, Sarita Shah11, Heidi Crane12, Richard Moore13, Raynell Lang2, Jennifer Thorne13, Timothy Sterling14, David B Hanna15, Kate Buchacz1. 1. Division of HIV Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 2. Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA. 3. Division of Infectious Disease, Emory School of Medicine, Atlanta, GeorgiaUSA. 4. Department of Biostatistics, Harvard University, Boston, Massachusetts, USA. 5. Division of Research, Kaiser Permanente Northern California, Oakland, California, USA. 6. Departments of Medicine & of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. 7. Kaiser Permanente Mid-Atlantic Permanente Research Institute, Rockville, Maryland, USA. 8. Division of Infectious Diseases, UT Southwestern Medical Center, Dallas, Texas, USA. 9. Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 10. Southern Alberta HIV Clinic, Calgary, Alberta, Canada. 11. Rollins School of Public Health & School of Medicine, Emory University, Atlanta, Georgia, USA. 12. Center for AIDS Research, University of Washington, Seattle, Washington, USA. 13. Johns Hopkins School of Medicine, Baltimore, Maryland, USA. 14. Vanderbilt University Medical Center, Nashville, Tennessee, USA. 15. Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, New York, USA.
Abstract
Background: In 2012, the US Department of Health and Human Services updated their HIV treatment guidelines to recommend antiretroviral therapy (ART) for all people with HIV (PWH) regardless of CD4 count. We investigated recent trends and disparities in early receipt of ART prescription and subsequent viral suppression (VS). Methods: We examined data from ART-naïve PWH newly presenting to HIV care at 13 North American AIDS Cohort Collaboration on Research and Design clinical cohorts in the United States during 2012-2018. We calculated the cumulative incidence of early ART (within 30 days of entry into care) and early VS (within 6 months of ART initiation) using the Kaplan-Meier survival function. Discrete time-to-event models were fit to estimate unadjusted and adjusted associations of early ART and VS with sociodemographic and clinical factors. Results: Among 11 853 eligible ART-naïve PWH, the cumulative incidence of early ART increased from 42% in 2012 to 82% in 2018. The cumulative incidence of early VS among the 8613 PWH who initiated ART increased from 83% in 2012 to 93% in 2018. In multivariable models, factors independently associated with delayed ART and VS included non-Hispanic/Latino Black race, residence in the South census region, being a male with injection drug use acquisition risk, and history of substance use disorder (SUD; all P ≤ .05). Conclusions: Early ART initiation and VS have substantially improved in the United States since the release of universal treatment guidelines. Disparities by factors related to social determinants of health and SUD demand focused attention on and services for some subpopulations. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2022.
Background: In 2012, the US Department of Health and Human Services updated their HIV treatment guidelines to recommend antiretroviral therapy (ART) for all people with HIV (PWH) regardless of CD4 count. We investigated recent trends and disparities in early receipt of ART prescription and subsequent viral suppression (VS). Methods: We examined data from ART-naïve PWH newly presenting to HIV care at 13 North American AIDS Cohort Collaboration on Research and Design clinical cohorts in the United States during 2012-2018. We calculated the cumulative incidence of early ART (within 30 days of entry into care) and early VS (within 6 months of ART initiation) using the Kaplan-Meier survival function. Discrete time-to-event models were fit to estimate unadjusted and adjusted associations of early ART and VS with sociodemographic and clinical factors. Results: Among 11 853 eligible ART-naïve PWH, the cumulative incidence of early ART increased from 42% in 2012 to 82% in 2018. The cumulative incidence of early VS among the 8613 PWH who initiated ART increased from 83% in 2012 to 93% in 2018. In multivariable models, factors independently associated with delayed ART and VS included non-Hispanic/Latino Black race, residence in the South census region, being a male with injection drug use acquisition risk, and history of substance use disorder (SUD; all P ≤ .05). Conclusions: Early ART initiation and VS have substantially improved in the United States since the release of universal treatment guidelines. Disparities by factors related to social determinants of health and SUD demand focused attention on and services for some subpopulations. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2022.
Entities:
Keywords:
ART initiation; Ending the HIV Epidemic Initiative; epidemiology; health disparity; viral suppression
Authors: Linda Beer; Heather Bradley; Christine L Mattson; Christopher H Johnson; Brooke Hoots; Roy L Shouse Journal: J Acquir Immune Defic Syndr Date: 2016-12-01 Impact factor: 3.731
Authors: Jennifer S Lee; Stephen R Cole; David B Richardson; Dirk P Dittmer; William C Miller; Richard D Moore; Mari Kitahata; Christopher Mathews; Kenneth Mayer; Elvin Geng; Chad J Achenbach; Joseph J Eron Journal: AIDS Date: 2017-09-10 Impact factor: 4.177
Authors: Richard M Novak; Rachel L D Hart; Joan S Chmiel; John T Brooks; Kate Buchacz Journal: J Acquir Immune Defic Syndr Date: 2015-09-01 Impact factor: 3.731
Authors: R Detels; A Muñoz; G McFarlane; L A Kingsley; J B Margolick; J Giorgi; L K Schrager; J P Phair Journal: JAMA Date: 1998-11-04 Impact factor: 56.272
Authors: Peter F Rebeiro; Alison G Abraham; Michael A Horberg; Keri N Althoff; Baligh R Yehia; Kate Buchacz; Bryan M Lau; Timothy R Sterling; Stephen J Gange Journal: AIDS Patient Care STDS Date: 2017-02-27 Impact factor: 5.078
Authors: Sharoda Dasgupta; Yunfeng Tie; Linda Beer; Jennifer Fagan; John Weiser Journal: J Assoc Nurses AIDS Care Date: 2021 Sep-Oct 01 Impact factor: 1.354
Authors: Jielin Zhu; Ignacio Rozada; Jummy David; David M Moore; Silvia A Guillemi; Rolando Barrios; Julio S G Montaner; Viviane D Lima Journal: EClinicalMedicine Date: 2019-07-10
Authors: Ann N Do; Eli S Rosenberg; Patrick S Sullivan; Linda Beer; Tara W Strine; Jeffrey D Schulden; Jennifer L Fagan; Mark S Freedman; Jacek Skarbinski Journal: PLoS One Date: 2014-03-24 Impact factor: 3.240